B38-CAP / Kafrelsheikh University 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
B38-CAP / Kafrelsheikh University
Bacterial ACE2, NCT04375046: Recombinant Receptors -Like Enzyme of B38-CAP Could be Promising Treatment for COVID-19 Infection- and Its Inflammatory Complications Better Than Recombinant Human ACE2

Not yet recruiting
1
24
NA
Recombinant Bacterial ACE2 receptors -like enzyme of B38-CAP (rbACE2)
Kafrelsheikh University, Foshan University Laboratory of Emerging Infectious Disease Institute of Translational Medicine The First Hospital of Jilin University China
COVID-19
08/21
10/21
NCT04382950: Combination of Recombinant Bacterial ACE2 Receptors -Like Enzyme of B38-CAP and Isotretinoin Could be Promising Treatment for COVID-19 Infection- and Its Inflammatory Complications

Not yet recruiting
1
24
NA
Recombinant Bacterial ACE2 receptors -like enzyme of B38-CAP (rbACE2) plus Aerosolized 13 cis retinoic acid
Kafrelsheikh University
COVID
08/21
10/21

Download Options